Intensive glycemic control and cardiovascular disease: an update.
Cardiovascular complications constitute the major cause of morbidity and mortality in patients with diabetes. The Diabetes Control and Complications Trial (DCCT) and the United Kingdom Prospective Diabetes Study (UKPDS) provided consistent evidence that intensive glycemic control prevents the development and progression of microvascular complications in patients with type 1 or type 2 diabetes. However, whether intensive glucose lowering also prevents macrovascular disease and major cardiovascular events remains unclear. Extended follow-up of participants in these studies demonstrated that intensive glycemic control reduced the long-term incidence of myocardial infarction and death from cardiovascular disease. By contrast, the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial, Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified Release Controlled Evaluation (ADVANCE) trial, and Veterans Affairs Diabetes Trial (VADT) results suggested that intensive glycemic control to near normoglycemia had either no, or potentially even a detrimental, effect on cardiovascular outcomes. This article discusses the effects of intensive glycemic control on cardiovascular disease, and examines key differences in the design of these trials that might have contributed to their disparate findings. Recommendations from the current joint ADA, AHA, and ACCF position statement on intensive glycemic control and prevention of cardiovascular disease are highlighted.
Brown
Aparna
A
Division of Endocrinology and Molecular Medicine, University of Kentucky, Wethington Building, Room 575, 900 South Limestone Street, Lexington, KY 40536-0200, USA.
Reynolds
L Raymond
LR
Bruemmer
Dennis
D
D015415:Biomarkers / Q000097:blood; D001786:Blood Glucose / Q000378:metabolism*; D002318:Cardiovascular Diseases / Q000097:blood / Q000209:etiology / Q000401:mortality / Q000517:prevention & control*; D002986:Clinical Trials as Topic; D003922:Diabetes Mellitus, Type 1 / Q000097:blood / Q000150:complications / Q000188:drug therapy* / Q000401:mortality; D003924:Diabetes Mellitus, Type 2 / Q000097:blood / Q000150:complications / Q000188:drug therapy* / Q000401:mortality; D019317:Evidence-Based Medicine; D006442:Glycated Hemoglobin / Q000378:metabolism*; D006801:Humans; D007004:Hypoglycemic Agents / Q000627:therapeutic use*; D018570:Risk Assessment; D012307:Risk Factors; D016896:Treatment Outcome
D015415:Biomarkers; D001786:Blood Glucose; D006442:Glycated Hemoglobin; D007004:Hypoglycemic Agents; C517652:hemoglobin A1c protein, human
BMJ. 2001 Jun 9;322(7299):1389-93
11397742
N Engl J Med. 2005 Dec 22;353(25):2643-53
16371630
Diabetes Care. 1979 Mar-Apr;2(2):120-6
520114
N Engl J Med. 2003 Jan 30;348(5):383-93
12556541
JAMA. 2004 Jan 21;291(3):335-42
14734596
N Engl J Med. 2008 Jun 12;358(24):2545-59
18539917
Diabetes Care. 2009 Jul;32(7):e90-1; author reply e92-3
19564469
JAMA. 1988 Nov 18;260(19):2864-71
3184351
N Engl J Med. 2009 Jan 8;360(2):129-39
19092145
Diabetes Res Clin Pract. 1995 May;28(2):103-17
7587918
Circulation. 2007 Jan 2;115(1):114-26
17192512
Diabetes Care. 2010 Jan;33 Suppl 1:S11-61
20042772
Diabetes Care. 2009 Jan;32(1):187-92
19092168
N Engl J Med. 2008 Jun 12;358(24):2560-72
18539916
N Engl J Med. 2008 Oct 9;359(15):1618-20
18843126
N Engl J Med. 1993 Sep 30;329(14):977-86
8366922
Ann Intern Med. 2004 Sep 21;141(6):421-31
15381515
N Engl J Med. 1993 Jun 10;328(23):1676-85
8487827
Lancet. 1998 Sep 12;352(9131):837-53
9742976
Ann Intern Med. 2009 Sep 15;151(6):394-403
19620144
Lancet. 2008 May 24;371(9626):1800-9
18502305
N Engl J Med. 1998 Jul 23;339(4):229-34
9673301
Lancet. 1998 Sep 12;352(9131):854-65
9742977
Circulation. 2007 Mar 27;115(12):1544-50
17353438
N Engl J Med. 2008 Feb 7;358(6):580-91
18256393
N Engl J Med. 2008 Oct 9;359(15):1577-89
18784090